Benzinga | Nov 2, 2020 09:02AM EST

BTIG Maintains Buy on Intra-Cellular Therapies, Lowers Price Target to $40

BTIG analyst Robert Hazlett maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and lowers the price target from $80 to $40.